Bruker Introduces Novel EVOQ™ DART-TQ+ for Chromatography-Free Mass Spectrometry Aimed at the Applied Market Segments
June 05 2023 - 6:00AM
Business Wire
- New EVOQ DART-TQ+ system for chromatography-free
triple-quadrupole mass spectrometry for point-of-need (PoN) routine
analysis
- Launch of impact™ II VIP ESI-TOF (time of flight) system for
highest sensitivity
- New TargetScreener™ 4D software bringing the selectivity of
TIMS (trapped ion mobility spectrometry) to high-confidence analyte
screening and quantitation
At the 71st ASMS meeting, Bruker Corporation (Nasdaq: BRKR)
highlights its commitment to develop novel technology and improved
mass spec workflows for the applied markets requirements of
robustness, ease-of-use, and highest confidence in food/beverage,
forensic/toxicology, industrial and environmental analysis.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230605005321/en/
EVOQ DART-TQ+ (Photo: Business Wire)
Chromatography-Free Point-of-Need (PoN) Applied
Workflows
Applied mass spectrometry is evolving to where customers require
simplified, robust, cost-effective and environmentally sustainable
workflows. In response, Bruker is introducing the unique
triple-quad (TQ) mass spectrometer EVOQ DART-TQ+, a
high-performance workhorse that enables straightforward routine
analysis from simplified tuning and method development through data
analysis and report generation for improved efficiency and
productivity. Featuring the first and only fully integrated
DART™ (Direct Analysis in Real Time) ionization source, the
EVOQ DART-TQ+ eliminates complex and time-consuming gas or
liquid chromatography for many point-of-need routine workflows.
Ultimate ESI-TOF Sensitivity for Applied and Metabolomics
Markets
Bruker launches new impact™ II VIP high-resolution QTOF
mass spectrometer with the novel VIP-HESI source, delivering
ultimate sensitivity for comprehensive screening and quantitation
tasks. Building on the proven reliability of the impact QTOF
series, new technical innovations further enhance the sensitivity
of the impact II VIP in Full-Sensitivity High-Resolution
mode with no compromise in high-performance mass resolution,
sensitivity, and dynamic range.
timsTOF for Ultimate Selectivity and Confidence
Bruker implements the new TargetScreener™ 4D which brings
the power of TIMS (trapped ion mobility spectrometry) to analyte
screening and quantitation. Backed by more than 2,400 measured and
predicted analyte CCS (collision cross section) values,
TargetScreener 4D provides ultimate confidence in highly
selective LC-TIMS-QTOF compound quantitation with even more
reliable identification.
Jeffrey Zonderman, President of the Bruker Applied Mass
Spectrometry division, commented: “With the world’s first fully
integrated DART-TQ-MS system, we are pioneering chromatography-free
workflows for the applied markets and for point-of-need mass spec
applications. We are excited to introduce the EVOQ DART-TQ+,
as simplified systems with greater ease of use, shorter analysis
times, lower cost of ownership, and significantly reduced solvent
usage are major steps in the evolution of ‘MS for the masses’.”
Jeffery Moran, Ph.D., Chief Executive Officer of PinPoint
Testing, LLC added: “As our company provides total solutions
ToxBox® kits for MS analysis in forensic toxicology, we see
a large opportunity to reduce complexity and cost for our
customers. We are pleased to collaborate with Bruker on
next-generation workflows, and the initial results look
fantastic.”
About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries
and develop new applications that improve the quality of human
life. Bruker’s high-performance scientific instruments and
high-value analytical and diagnostic solutions enable scientists to
explore life and materials at molecular, cellular, and microscopic
levels. In close cooperation with our customers, Bruker is enabling
innovation, improved productivity, and customer success in life
science molecular and cell biology research, applied and pharma
applications, microscopy and nano analysis, as well as industrial
applications. Bruker offers differentiated, high-value life science
and diagnostics systems and solutions in preclinical imaging,
clinical phenomics research, proteomics and multiomics, spatial and
single-cell biology, functional structural and condensate biology,
as well as clinical microbiology and molecular diagnostics. Please
visit www.bruker.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230605005321/en/
Media Contact Meghan Martell Bruker Marketing
Communications T: +1 (603) 809-3287 E:
meghan.martell@bruker.com
Investor Relations Contact Justin Ward Sr. Director
Investor Relations & Corp Development T: +1 (978) 313-5800 E:
Investor.Relations@bruker.com
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024